July 2022 "July 19, 2022 07:00 AM Eastern Daylight Time BOSTON-- Tectonic Therapeutic , Inc. a pre-clinical

., Tectonic ’s SVP, Head of Research. Peter joined Tectonic to help chart new territory in GPCR science. We’re glad to have Peter's dedication, experience, and passion in building innovative therapeutics."

for Drug Discovery DMS: Linking Protein Structure To Function AbbVie Completes Acquisition of Cerevel Therapeutics Nxera Pharma attended the Drug Discovery Ecosystem Summit Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million Tectonic Therapeutic Announces

< GPCR News < GPCRs in Oncology and Immunology Noval insights and therapeutic strategies for tumor-induced receptor (TACR3), a homolog of the G protein-coupled receptor TkR99D in fruit flies, as a potential therapeutic The implications of these findings for transforming the therapeutic approaches to renal complications These insights could contribute to the advancement of diagnostic and therapeutic strategies for treating

Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and

< GPCR News < GPCRs in Oncology and Immunology Expanding role of CXCR2 and therapeutic potential of CXCR2 date, many small-molecule CXCR2 antagonists have entered clinical trials, showing favorable safety and therapeutic